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Background: Mycosis fungoides (MF), the most common subtype of cutaneous T-Cell Lym-
phoma (CTCL), is a rare chronic skin neoplasia. Total skin electron irradiation has been
employed along with a variety of other topical or systemic treatments for MF  management.
Aim: To report the ﬁrst case treated by TSEB irradiation protocol in Greece.
Materials and methods: A fractionated 36 Gy total skin electron beam (TSEB) therapy was
prescribed to a 65-years-old male patient with mycosis fungoides (MF), stage IIB, refractory
to  several treatments during a 20-year period. Dose uniform delivery was monitored by
thermo-luminescence dosimetry.
Results and discussion: The homogeneous skin dose distribution resulted in a complete clin-
ical  response. Limited, irradiation-oriented, side effects appeared.Conclusions: The ﬁrst TSEB irradiation prescription in Greek medical chronicles was proved
effective in this case of tumor stage MF (T3-IIB), which had been refractory to several single
or  combination treatments.
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
cytostatics, biologics, etc). An available treatment of the MF
is radiation therapy all over the skin surface by utilizing low1.  Background
Mycosis fungoides (MF) is a cutaneous T-Cell Lymphoma
(CTCL) that involves the skin and derives from malignant
T-lymphocytes. It is a chronic, progressive, and quite rare non-
1,2Hodgkin lymphoma. The prevalence of MF in the United
States of America is 3:106.3 The vast majority of patients are
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between 45 and 69 years of age at diagnosis,3 without exclud-
ing even childhood patients.1,4
Management of MF is stage-dependent and consists of a
wide spectrum of treatments (corticosteroids, phototherapy,
1Hospital ‘Attikon’, 01 Rimini Str., 124 62 Chaidari, Athens, Greece.
energy electrons (4–9 MeV), produced by a linear accelerator.3–8
This technique is referred in current literature as total skin
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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lectron beam (TSEB) therapy.3,8 This modality differs from
onventional radiation protocols as the patient is irradiated
t an off-couch setup.3 The creation of wide electron ﬁelds is
chieved either by exploiting an extended source to skin dis-
ance (SSD) (≈7 m)  or by the matching of two or more  angled
lectron beams at a shorter SSD (≈2–4 m).  TSEB irradiation
an be performed mainly by applying three different treat-
ent techniques, according to patient setup in respect to the
nlarged static electron ﬁeld: (a) standing patient techniques
 patient takes at each session certain positions of treatment,
b) rotary techniques – with simultaneous rotation and irradi-
tion of the skin, and (c) translational techniques – patient
lides through the static broad electron beam. In addition,
o accomplice these irregular setups of treatment, specially
esigned equipment should be provided for the modulation
f the electron beam and a proper positioning and immobi-
ization of the patient at each treatment session.3–8
.  Aim
his study presents the case of a 65-years-old male patient
ith mycosis fungoides (MF) stage IIB refractory to previous
reatments, treated with total skin electron beam (TSEB) ther-
py who  achieved a complete clinical response (CCR). This is
he ﬁrst case ever to be treated with TSEB irradiation protocol
n Greece.
.  Materials  and  methods
n March 2011, a 65-year-old patient stage IIB9 MF, refrac-
ory to several treatments, as neotigason, interferon alpha
INFa), bexarotere, in combination with psoralen and ultravi-
let A (PUVA) treatment, has been referred for TSEB therapy
t the Radiation Therapy unit of the University General Hos-
ital “Attikon”. From his medical history, he had a cutaneous
asal-cell cancer in the region of the left supraorbital arch con-
ronted by surgical removal and a 10-days radiation therapy
cheme 37 years ago. His MF  was diagnosed 20 years ago. At
he time of referral he had multiple ulcerated plaques on his
runk and thighs, and two large tumors at the inner site of his
eft knee, despite INFa treatment 3.000.000 × 3 times weekly,
hich was discontinued at the time of initiation of TSEB.
e also suffered from severe pruritus. His modiﬁed severity
eighted assessment tool (mSWAT) score10 was 194.5.
Additional investigations included biopsy from the recent
umor located in the inner thigh, ﬂow cytometry and clon-
lity of peripheral blood T cells and computed tomography
CT) scans. Histology from the skin biopsy revealed a tumor
F with cluster of differentiation (CD)3+, CD4+, CD8−, CD7+,
D30+ immunophenotype. Flow cytometry of the peripheral
lood showed a Th2 immunophenotype with an increase
f intracytoplasmic interleukin-4 (IL-4) and T-cell receptor
CR rearrangement of the CD3 gene was shown by poly-
erase chain reaction (PCR). He also had reactive inguinalymphadenopathy. CT scans from his thorax, upper and lower
bdomen were not consistent with extracutaneous spread.
ymph nodes were not drained and there was no involvement
f any visceral organ. Bone marrow biopsy was normal.therapy 1 9 ( 2 0 1 4 ) 114–119 115
Pre-treatment CT scan and laboratory examinations
revealed no essential differentiation in his clinical condition
since 2008, good thyroid functions, and normal hematology,
with limited leucopenia due to IFNa treatment (white blood
cell (WBC) count: 2600, neutrophil (Neut) count: 1600).
Total skin electron beam therapy was initiated.3,9,11 The
patient was irradiated by utilizing the recently established in
our unit 6-dual ﬁeld TSEB irradiation technique, as described
by Platoni et al.12 An enlarged and uniform electron ﬁeld of
200 cm × 80 cm is formed by two individual, angled (252.5◦
and 287.5◦), 36 cm × 36 cm,  6 MeV electron ﬁelds. The ability
of producing such large electron ﬁelds without any electron
applicator is provided by the high dose total skin electron
(HDTSe−) mode which is available on our Clinac 2100C (Varian
Medical Systems, Palo Alto, CA) linear accelerator. Dose rate
is automatically set at almost 2500 MU/min at isocenter. The
treatment plane is located at 2.8 m from the linear accelera-
tor’s isocenter. A large polymethyl methacrylate (PMMA) panel
(203 cm × 111 cm and thickness of 0.5 cm), homogenates the
produced ﬁeld 30 cm before treatment plane. This attenuator
is attached to a home-made patient support-system. In this
system, patient is aligned in respect to the gantry of the linear
accelerator and treatment can be performed at 240◦, 0◦, 120◦,
300◦, 180◦ and 60◦, by patient’s gradual rotation, resulting in
total skin irradiation.
Due to extent of skin involvement, the prescribed dose was
3600 cGy,12–14 fractionated in a daily dose of 200 cGy, following
a two-day irradiation cycle, in order to fully cover his body sur-
face (Fig. 1). The treatment course, started on the 6th of June
2011, was completed in nine weeks without any interval and
consisted of two irradiation cycles (four days) per week. During
beam-on time, the eyes, nails, and genitals were shielded by
lead blocks of at least 0.4 cm in thickness, till the completion of
the treatment, in order to avoid radiation side effects. The nails
were covered due to the lack of MF lesions but mainly to pro-
tect them from radiation induced toxicity (e.g. melanonychia).
The shields were taped on the nails at each session. Eyes were
protected by a lead-ﬁlled pair of goggles (1.5 cm of lead), and
genitals by a 0.4 cm lead sheet attached to the inner surface of
a jockstrap.
After the ﬁrst 2000 cGy, the vertex of the scalp was also cov-
ered by a lead helmet of 0.4 cm in thickness in order to restrain
hair loss. The shielding of the scalp was decided after consid-
ering the results of the daily “in vivo” dosimetry, as in this
region an excess amount of 120% (average) of the prescribed
dose was delivered continually.
For accurate determination of the dose delivered to the
patient, 80 thermo-luminescence (TL) detectors (GR200A) were
distributing to patient’s body uniformly on a daily basis, for
the ﬁrst four weeks of treatment. After this period and until
the completion of the treatment, only a district number of TL
detectors (60) were utilized, for practical reasons. Dosimeters
were placed on certain positions every day, focusing especially
on areas of irregular beam incidence. For further assistance, a
human-ﬁgure drawing with premarked numbered spots was
guiding TL detectors’ positioning every day. Moreover, the
points of “in vivo” dosimetry were dyed with fuchsine on
the skin to ensure reproducibility of our measurements. The
detectors were placed on spots of increased interest, such as
potential underdosed regions on the body (axillae, perineum,
116  reports of practical oncology and radiotherapy 1 9 ( 2 0 1 4 ) 114–119
f treFig. 1 – TSEB therapy positions during (a)–(c) ﬁrst day o
various body folds, etc.). In addition, ten of the dosemeters
were always pasted at reference and normalization point
(umbilicus) and at plane surfaces of the body (chest, back,
limbs, etc.). Results were retrieved from the daily dose map-
ping procedure (36 measurements in total at 60 premarked
spots on the skin). The detectors were handled within opaque
and numbered paper envelopes. Calibration, annealing and
signal acquirement were performed by an ETT annealing ovenatment cycle and (d)–(f) second day of treatment cycle.
(Fimel, Vélizy, France) and a Manual thermo-luminescence
dosimetry (TLD) reader (Fimel, Vélizy, France).
The calibration of the detectors occurred at an on-couch
setup, utilizing a 10 cm × 10 cm electron applicator, SSD of
1 m,  build-up and backscatter PMMA of 0.8 cm and 15 cm,
respectively, irradiated at the same nominal energy (6 MeV) of
TSEB therapy performance, which resulted in mean electron
energy at treatment plane of 3.4 MeV. To conﬁrm the validity of
reports of practical oncology and radiotherapy 1 9 ( 2 0 1 4 ) 114–119 117
Fig. 2 – Percentage mean dose distribution on patient skin from all irradiation sessions. (a) Anterior side. (b) Posterior side.
Fig. 3 – Clinical condition of patient at (a) the 4th week of irradiations (b) the end of the treatment (c) one month after the
completion of TSEB procedure.
118  reports of practical oncology and radiotherapy 1 9 ( 2 0 1 4 ) 114–119
Fig. 4 – (a) Mycosis fungoides on the back of the patient (4th week of treatment). (b) Complete regression of the disease on
the back one month after the end of the treatment. (c) Region that resisted treatment (end of TSEB irradiation procedure). (d)
s.Residual disease, 1 month after the completion of irradiation
calibration for TSEB irradiation setting, 10 randomly selected
detectors from the already calibrated patch were also irradi-
ated in TSEB therapy setup (positioned vertically in relation
to the 270◦ gantry angle position). The dose delivered to the
detectors was 1 Gy. The corresponding monitor units (MU)
were calculated by utilizing a parallel plate ionization cham-
ber Roos® (PTW, Freiburg, Germany) connected to a Unidos®
electrometer (PTW, Freiburg, Germany). The mean value of
the acquired readings was compared to the mean reading
retrieved by the on-couch dose delivery.
The coincidence of dosemeters’ response in the different
setups was calculated by the formula:
D (%) = |R¯TSEB − R¯Couch|
R¯Couch
× 100% (1)
where D is the percentage deviation of the two measurements;
R¯TSEB is mean TL detector reading acquired at TSEB irradia-
tion conditions; R¯couch is mean TL detector reading acquired at
standard calibration conditions.
The deviation between the two dose measurements was
less than 1% (0.4%). Thus, the initial calibration was consid-
ered reliable to be used for the “in vivo” dose determination.4.  Results  and  discussion
“In vivo” measurements revealed quite a homogeneous dose
distribution on the skin (Fig. 2). Mean percentage dose on the
skin was 101% of the prescription, showing a standard devi-
ation of ±10.5%. The maximum percentage dose value was
138% (region of the feet) and the minimum 85% (arms).
The majority of underdosed areas appeared in the neck and
supraclavicular area, armpits, hands, bubonic area and gluteal
creases, as it was expected due to human body curvature. Con-
versely, the head and the lower part of the legs (tibiae and feet)
seemed to be overdosed.
First side effects appeared at the second week of irradi-
ation. The response of the skin to the treatment was acute:
skin erythema, lesion exaltation, bleeding, wet desquamation,
moderate edema, epilation, local pruritus, and fatigue. These
symptoms continued until the sixth week of irradiation, when
they started to withdraw. At the middle of the treatment, the
patient had topical alopecia. Until the ninth week, all lesions
were transformed into white patches on a lightly browned
skin (Figs. 3 and 4a and b). The region that seemed to resist
treatment was the skin of the left loin (Fig. 4c and d). On  this
anatomical area, two pairs of 6 MeV  electron boost ﬁelds, sized
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0 cm × 10 cm,  were applied after the completion of the whole
kin irradiation in order to deliver a total of 100 cGy to this
egion. The soles of the feet (although under-dosed) were not
urther irradiated due to the lack of MF  lesions.
One month later, the face of the patient remained erythe-
atic and the loss of ﬁngernails was observed. Moreover, the
atient reported lacrimation. The disease in the treatment-
esisting area of the left loin did not regress, while the rest
f the skin responded positively in total to radiation. The
roblematical area, related to underdosed lesions (<90% of
rescribed dose) was re-irradiated with one additional session
f 600 cGy, delivered by regional electron boost ﬁelds of 6 MeV.
After the initiation of TSEB therapy, he gradually showed
mprovement in ulceration and reduction of tumors and at the
nd of the 36 sessions of treatment had a CCR which means a
omplete disappearance of his lesions. Four months later, he
as otherwise well with only a few new small pruritic nodules
n his arms mimicking prurigo nodularis, which histologically
ere consistent with MF.  These lesions are currently treated
ith topical steroids. He is feeling well and ﬁt. According to
he patient, this is the best result comparing to any previous
reatment. However, one year post TSEB treatment he had a
igger relapse and was restarted on IFNa until today.
.  Conclusion
his is an interesting case of tumor stage MF (T3-IIB) which
ad been refractory to all medical treatments including com-
ination treatment, showed progression despite treatment (T2
o T3) and was an absolute indication for full dose of 36 Gy of
SEB therapy.
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